CAR T-cell Therapy Drug Pipeline Market Research Report 2022: Insights About 300+ Companies and 300+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CAR T-cell Therapy – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in CAR T-cell Therapy pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-cell Therapy R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-cell Therapy.

CAR T-cell Therapy Emerging Drugs Chapters

This segment of the CAR T-cell Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CAR T-cell Therapy Emerging Drugs

JWCAR029: JW Therapeutics

JWCAR029 is a CAR-T cell product targeting CD19, which is intended to treat late-stage lymphoma and leukemia (Second-line therapy or greater). The molecule is in phase-II stage of development. Initially, JWCAR029 is being studied for the treatment of B-cell malignancies focusing on relapsed and refractory DCBCL. In June 2020, the National Medical Products Administration (“NMPA”) accepted for review its NDA relating to relma-cel as a third-line treatment for DLBCL. The drug is currently in preregistration stage for the treatment of Diffuse large B cell lymphoma.

Descartes-11: Cartesian Therapeutics

Descartes-011 are autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor. Descartes-11 is currently in phase II clinical trials to treat patients with multiple myeloma in an outpatient setting.

CNCT19: CASI Pharmaceuticals

CNCT19 is being developed by CASI Pharmaceuticals in collaboration with Juventas Cell Therapy. CNCT19 is currently in Phase II for Non-Hodgkin’s Lymphoma, Relapsed or Refractory Acute Lymphoblastic Leukemia and Phase I/II for Large B-cell Lymphoma.

CTL119: Novartis

CTL119 (CD19 CAR) is a humanized CD19 CAR under development by Novartis in collaboration with the University of Pennsylvania and currently is in Phase II stage for the treatment of Acute Lymphoid Leukemia. CTL119 is produced with a patient’s T-cells, some of which are removed and then reprogrammed in Penn’s Clinical Cell and Vaccine Production Facility with a gene transfer technique designed to demonstrate the T cells to target and kill tumor cells.

The engineered cells contain an antibody-like protein known as a CAR, which is designed to bind to CD19 protein on the surface of cancerous B cells. The modified “hunter” cells are then infused back into the patient’s body, where they multiply and are believed to attack the cancer cells.

P-BCMA-101: Poseida Therapeutics

P-BCMA-101 is the company’s leading investigational CAR-T immunotherapy designed to supercharge a patient’s T-cells to safely and effectively eliminate tumor cells carrying B cell maturation antigen (BCMA), which is expressed on essentially all multiple myeloma cells. It modifies a patient’s T-cells using piggyback Transposon System, which enables several desirable features.

It is a next-generation CAR T-cell therapy designed to maintain very potent and durable activity against BCMA, an antigen target expressed on essentially every multiple myeloma cell. P-BCMA-101 encodes a CARTyrin that targets the B-cell maturation antigen (BCMA) for the treatment of multiple myeloma (MM) and has several unique aspects that improve upon earlier CAR T products. It is currently in phase 2 of development stage for the treatment of multiple myeloma.

AUTO4: Autolus Limited

AUTO4 is a programmed T-cell therapy product candidate being developed by Autolus Limited to leverage a new targeting approach based on the mutually exclusive expression of two subtypes of the T-cell receptor beta chain: AUTO4 targets TRBC1, while another of the company’s product candidates in development, AUTO5, targets TRBC2. Normal T-cells contain both TRBC1 and TRBC2 compartments, whereas T-cell lymphoma cells are derived from mature cells and express only TRBC1 or TRBC2. The therapeutic candidate is in phase I/II of development for the treatment of patients with relapsed or refractory TRBC1-positive selected PTCL.

Descartes-08: Cartesian Therapeutics

Descartes-08 is a CD8+ CAR-T investigational therapy that targets cells expressing B-cell Maturation Antigen (BCMA), a protein expressed by all plasma cells. Descartes-08 is engineered to have a defined and predictable half-life, enabling repeat dosing to maximize potency while minimizing risk of toxicity. Descartes-08’s enhanced safety features enable use for of a wide range of diseases, from multiple myeloma and other cancers to autoimmune diseases. Descartes-08 is currently in Phase I/II clinical trials to treat patients with multiple myeloma in an outpatient setting.

ET140202: Eureka Therapeutics

Eureka Therapeutics is developing ET140202 (also known as ET1402; ET1402L1), an investigational CAR T-cell therapy for treating hepatocellular carcinoma (HCC) which is the most common type of liver cancer. The therapeutic candidate is a humanized antibody, identified from Eureka’s proprietary ALPHA phage library, which selectively targets liver cancer cells overexpressing alpha-fetoprotein (AFP). ET1402 is selective and specific for the AFP158-166 peptide complexed with human leukocyte antigen (HLA)-A*02:01. The company, in collaboration with the City of Hope, is evaluating ET1402 in the phase I/II stage of development for the treatment of Liver Cancer.

MB-102: Mustang Bio

Mustang Bio (a subsidiary of Fortress Biotech) is developing MB-102 which is a CAR T-cell therapy that contains a CD123 antigen targeted antibody scFv with a co-stimulatory domain CD28 and an essential activating domain CD3? as well as the extracellular domain of EGFR (EGFRt) as a selection/safety marker. It is in Phase I/II clinical trials for the treatment of acute myeloid leukemia (AML).

AU101: Aurora Biopharma

AU101 is under development by Aurora Biopharma. It is a chimeric CAR T-cell therapy that contains a HER2 targeted antibody scFv with a costimulatory domain CD28 and an essential activating domain CD3, transfected to autologous CMV-pp65 T-cells using a retroviral virus. The therapeutic candidate is in phase I/IIa stage of development for the treatment of Recurrent Glioblastoma; Sarcoma/Osteosarcoma. The therapeutic CAR T-cell agent targets HER2 expression. Preclinical animal studies with different cancers showed that AU101 killed tumors in various cancers in around two weeks. Aurora has a clinical trial collaboration to conduct CAR T trials with Baylor College of Medicine, Texas Children’s Hospital and Baptist Methodist Hospital in Houston, Texas.

CAR T-cell Therapy: Therapeutic Assessment

This segment of the report provides insights about the different CAR T-cell Therapy drugs segregated based on following parameters that define the scope of the report.

CAR T-cell Therapy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-cell Therapy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-cell Therapy drugs.

Key Players

• Sorrento Therapeutics
• Cartesian Therapeutics
• CASI Pharmaceuticals
• Novartis
• Poseida Therapeutics
• Shanghai Unicar-Therapy Bio-medicine Technology
• Sinobioway Cell Therapy Co., Ltd.
• Gilead Sciences
• Tessa Therapeutics
• Wuhan Bio-Raid Biotechnology
• Autolus Limited
• Beijing Immunochina Medical Science and Technology
• BioAtla
• BioInvent International
• Carsgen Therapeutics
• Chongqing Precision Biotech
• Eureka Therapeutics
• Formula Pharmaceuticals
• Guangzhou Bio-gene Technology
• Hebei Senlang Biotechnology
• Mustang Bio
• MolMed
• Aurora BioPharma
• Atara Biotherapeutics
• Bellicum Pharmaceuticals
• Kecellitics Biotech Company Ltd
• Yake Biotechnology
• Minerva Biotechnologies
• Shanghai GeneChem Co., Ltd.
• Allogene Therapeutics
• Miltenyi Biotec
• PersonGen BioTherapeutics (Suzhou)
• Precision BioSciences
• Takara Bio
• BioNTech
• Miltenyi Biomedicine
• CRISPR Therapeutics
• Celgene
• Cellectis
• Celyad
• Gracell Bio
• Servier
• Protheragen
• Noile-Immune Biotech
• Arcellx Inc
• HRAIN Biotechnology
• Tmunity Therapeutics Inc.
• AffyImmune Therapeutics
• Maxcyte
• Kuur Therapeutics
• TILT Biotherapeutics
• Targazyme
• TC BioPharm
• Takeda
• Sensei Biotherapeutics
• Sana Biotechnology
• Oncternal Therapeutics
• Humorigin
• Fate Therapeutics
• Enlivex Therapeutics Ltd
• Exuma
• Caribou Biosciences
• Arbele Limited
• Adicet Bio

Key Products

• CEA CAR-T
• Descartes-11
• CNCT19
• CTL119
• P-BCMA-101
• EPCAM-targeted CAR-T cells
• KTE-X19
• TT11
• AUTO4
• AUTO3
• IM19 CAR-T
• CAB-AXL-ADC
• CAB-ROR2-ADC
• CSG-CD19
• CT053
• Descartes-08
• PCAR-19B
• BCMA CAR-T cells
• ET140202
• CIK-CAR.CD19
• BG-T19
• Autologous CD19-targeting CAR T cells (Senl-001)
• MB-102
• Autologous CAR-T CD44v6 cell therapy
• AU101
• ATA2271
• AUTO1
• BPX-601
• CD123 CAR T cell therapy
• Anti-CD22 CAR
• huMNC2-CAR44 CAR T-cells
• ALLO-501A
• AUTO1/22
• ET 1402L1-CART
• BPX-603
• MB CART 20.1
• MB-106
• PCAR-019
• Anti-MUC1 CAR-T cells
• PBCAR0191
• PBCAR269A
• TBI-1501
• BNT211
• MB-CART19.1
• iCarTAB BioMed
• CTX101
• Bluebird Bio
• bb21217
• JCAR 018
• UCART123
• CYAD-02
• GC027
• NIB-102
• TMUN ONC 001
• AIC100
• MCY-M11
• KUR-501
• TILT-T392
• TZ-102

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/mpy1k7

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900